SBC Medical Group Holdings(SBC)
$7.35+2.01 (+37.64%)
SBC
SBC Medical Group Holdings earnings date
$7.35
At close:+2.01 (+37.64%)
Want to see SBC full AI Analyst Report?
SBC Medical Group Holdings (SBC) Q3 2026 Earnings Report
40 Followers
SBC Q3 2026 EPS Results
- Actual EPS
- $0.15
- Consensus EPS
- $0.12
- Beat/Miss
- Beat by +$0.03
- One Year Ago EPS
- $0.12
SBC Q3 2026 Revenue Results
- Actual Revenue
- $58.58M
- Expected Revenue
- $48.90M
- Beat/Miss
- Beat by +$9.68M
- YoY Revenue Growth
- +35.13%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/13/2026
- Time
- Before Open
- Conference Call
- Friday, November 13, 2026
SBC Upcoming Earnings
SBC Medical Group Holdings's next earnings date is estimated for March 26, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
SBC Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was strongly positive, led by 35% revenue growth, 66% growth in operating income and adjusted EBITDA, a 47% adjusted EBITDA margin, healthy same-clinic trends, continued network expansion, and several AI, longevity, and international growth initiatives. The main concerns were ongoing governance issues, intense competition in Japan, limited near-term longevity revenue, room for greater U.S. capital-market recognition, and the decision not to pursue an additional share buyback at present.
Company Guidance
Management said the clinic network can expand “continuously with almost same pace as this year” in “the next year,” alongside planned M&A and de novo openings; longevity is expected to provide “meaningful revenue contribution from around 2028,” with longevity centers to open “next year” and a roadmap through 2028; AI-related profitability is expected to “improve going forward to some extent,” while adjusted EBITDA margin can rise “further over the medium to long-term,” with “big room for the margin to expand in the near future”; in the U.S., SBC-branded clinics may appear in “the next 6 to 12 months,” OrangeTwist is expected to open “at least one more this quarter” and potentially “8-10 in the next three to four months,” and the company is “not considering additional share buyback at this moment.”
- Strong Third-Quarter Revenue and Profit GrowthThird-quarter revenue rose 35% year-on-year to $59 million, income from operations increased 66% to $26 million, and adjusted EBITDA increased 66% to $28 million. Basic EPS was $0.15, up 25% year-on-year.
- Significant Margin ExpansionAdjusted EBITDA margin reached 47%, improving 9 points year-on-year. Operating margin expanded from 37% to 45% year-on-year, with management attributing the faster profit growth to operating leverage in the MSO model.
- Healthy Same-Clinic PerformanceFor the first nine months, same-clinic revenue reached $836 million, up 7% year-on-year. Over the trailing 12 months, customer visits increased 9% to 7.06 million, unique customers increased 10% to 2.26 million, and average spend per visit rose 4% to $290.
- Continued Clinic Network ExpansionThe clinic network expanded by 36 locations year-on-year to 293 locations. Management expects to continue expanding aesthetic clinics at almost the same pace as this year, while also growing general medicine networks in dentistry, orthopedics, and ophthalmology and pursuing M&A.
- Multiple Drivers of Revenue GrowthRevenue increased by $15.2 million year-on-year. Management services revenue rose 73% year-on-year, reflecting the service fee revisions announced in August together with lower promotional costs in the points business; rental revenue grew from medical equipment installed at newly opened clinics; and the newly consolidated Waqoo segment contributed $5.6 million.
- Net Income GrowthNet income attributable to SBC Medical increased 22% year-on-year, supported by strong growth in the core business.
- Strategic Pricing and Medical Offering ImprovementsManagement said strategic pricing over the past two years strengthened the company's competitive position and enabled price increases for some treatments. The company also introduced state-of-the-art medical equipment and treatments, including expanding the NEO Skin Clinic network with a wide variety of laser equipment, contributing to higher average spend per visit.
- Longevity Roadmap Through 2028The company established a staged longevity roadmap through 2028. It plans to begin its own blood biomarker testing program in November 2026, establish a longevity center and online coaching and tracking platform in 2027, and develop AI-generated, doctor-verified treatment protocols while exploring expansion into the United States through OrangeTwist and Southeast Asia in 2027 and 2028.
- Development of Diagnostic CapabilitiesSBC has begun in-house development of a DNA methylation test to estimate biological age. The research focuses on organ-by-organ mapping of biological age, non-invasive measurement methods that do not require a blood draw, and data specific to Japan. Management expects meaningful longevity revenue contribution from around 2028.
- AI Platform and Six Planned AI FeaturesThe company is building its own local large language model foundation to use patient data safely, develop proprietary features from clinical and customer data, and decouple inference costs from cloud API pricing. Planned features cover cost, risk, and revenue, including voice-driven automatic charting designed to draft a medical record in about one second, AI shift scheduling, clinical-system and data-access monitoring, a clinic promotion planner, a treatment-plan recommendation engine using 26 years of case data, and personalized customer recommendations.
- AtomicSoftware AllianceSBC entered a capital and business alliance with AtomicSoftware, provider of medicalforce, which is adopted by more than 800 clinics and has a 99.2% retention rate. The companies plan to co-develop AI features, implement them in SBC's systems, and extend them to new brands and formats.
- International Brand RecognitionShonan Beauty Clinic was selected in two plastic surgery categories in Newsweek's World's Best Hospitals & Clinics for Medical Tourism 2027, with liposuction and breast augmentation each ranked among the top 75 facilities in the world. In 2025, doctors from the group presented research at 28 medical conferences in Japan and abroad, with 75 physician appearances.
- Improving Trading Liquidity and Shareholder BaseAverage daily trading value in October was approximately $1 million, about 4.1 times the July level. Beneficial shareholders reached 7,300 as of October 2026, a 1.6x increase since July 2026. Through October, the company held 183 one-on-one investor meetings and participated in 22 IR conferences.
- U.S. and OrangeTwist Expansion ProgressSBC is continuing to work with minority-owned OrangeTwist on clinic expansion, with at least one additional opening planned for the quarter and a goal of adding 8 to 10 clinics over the next three to four months. The company is also conducting market research for SBC-branded U.S. clinics and said such clinics may appear in the next 6 to 12 months.
- Promising Multi-Brand Clinic PerformanceManagement said the renamed SBC Skin Clinic locations, SBC MEN'S FLASH CLINIC, and new JUN CLINIC openings are performing promisingly and generating good revenue by addressing diversified customer needs. The SBC Skin Clinic branding change is attracting customers seeking light, non-surgical treatments more frequently.
- Net Cash Funding Growth InitiativesManagement highlighted a net cash balance sheet and said the company funds its initiatives from operating cash flow. Capital investment priorities are M&A and opening de novo clinics, alongside continued investment in longevity and AI utilization.
- Expected Further Margin ExpansionManagement believes adjusted EBITDA margin can rise further over the medium to long term, driven by higher service fees from improved clinic productivity, AI-enabled service improvements, and operating leverage as the clinic network expands.
SBC Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 26, 2027 | 2026 (Q4) | 0.12- | 0.14 | ― | ― |
| Nov 13, 2026 | 2026 (Q3) | 0.120.15 | 0.12 | 25.00% (+0.03) | |
| Aug 13, 2026 | 2026 (Q2) | 0.120.10 | 0.02 | 400.00% (+0.08) | |
| May 14, 2026 | 2026 (Q1) | 0.100.11 | 0.21 | -47.62% (-0.10) | |
| Mar 27, 2026 | 2025 (Q4) | 0.120.14 | 0.06 | 133.33% (+0.08) | |
| Nov 14, 2025 | 2025 (Q3) | 0.110.12 | 0.03 | 300.00% (+0.09) | |
| Aug 13, 2025 | 2025 (Q2) | 0.140.02 | 0.2 | -90.00% (-0.18) | |
| May 15, 2025 | 2025 (Q1) | 0.150.21 | -0.06 | 481.82% (+0.27) | |
| Mar 28, 2025 | 2024 (Q4) | 0.170.06 | -0.04 | 236.36% (+0.10) | |
| Nov 13, 2024 | 2024 (Q3) | ―0.03 | -0.02 | 257.89% (+0.05) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
